Study guide

11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis

Key Takeaways Explain This Topic AI

Thyroid storm is a hypermetabolic crisis diagnosed clinically via the Burch-Wartofsky Point Scale (score >= 45 highly suggestive); management requires immediate execution of the quadruple drug therapy sequence without waiting for confirmatory laboratory results.

The quadruple therapy for thyroid storm follows a mandatory timing sequence: Step 1 thionamide (propylthiouracil 500–1,000 mg load then 250 mg q4h, often preferred over methimazole due to peripheral T4-to-T3 blockade), Step 2 inorganic iodine (SSKI or Lugol's solution administered AT LEAST 1 hour AFTER thionamide to prevent the Jod-Basedow phenomenon), Step 3 beta-blockade (propranolol or esmolol), and Step 4 systemic corticosteroids (hydrocortisone or dexamethasone).

Administering inorganic iodine prior to thionamide-mediated organification blockade provides exogenous iodine substrate that accelerates de novo thyroid hormone synthesis (Jod-Basedow effect), worsening hyperthyroidism; waiting >= 1 hour ensures the Wolff-Chaikoff effect blocks preformed hormone release.

Myxedema coma is characterized by severe hypothermia, profound bradycardia, hypoventilation, and obtundation; treatment requires IV levothyroxine (T4 200–400 mcg load) +/- IV liothyronine (T3 5–20 mcg), with stress-dose hydrocortisone (100 mg IV q8h) administered BEFORE or CONCURRENTLY with thyroid hormone to avoid precipitating fatal adrenal collapse.

Acute adrenal crisis (refractory shock, hyponatremia, hyperkalemia, hypoglycemia) is treated with hydrocortisone 100 mg IV immediately, then 200 mg/24 h, plus dextrose-saline; never delay steroids for testing, and reserve dexamethasone for undiagnosed patients who must have a cosyntropin test first.

Last updated: October 2026

11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around clinical emergency medicine pharmacotherapy principles and critical care endocrine guidelines.

Thyroid Storm: Pathophysiology & Burch-Wartofsky Point Scale

Thyroid storm is an extreme, life-threatening manifestation of thyrotoxicosis characterized by multiorgan decompensation under hypermetabolic adrenergic stress. Mortality approaches 10% to 30% if untreated. Precipitating events include systemic infections, trauma, non-thyroidal surgery, discontinuation of antithyroid medications, diabetic ketoacidosis, pulmonary embolism, toxemia of pregnancy, and exposure to iodinated radiocontrast media.

Clinical Manifestations

Excess circulating free thyroid hormones (thyroxine [ T 4 T_4 T 4 ​ ] and triiodothyronine [ T 3 T_3 T 3 ​ ]) dramatically upregulate myocardial and peripheral beta-adrenergic receptor density and sensitivity. The clinical picture is dominated by hyperadrenergic hyperactivity, severe thermoregulatory failure (hyperpyrexia up to 104 to 106 ∘ F / 40 to 41.1 ∘ C 104\text{ to }106^\circ\text{F} / 40\text{ to }41.1^\circ\text{C} 104 to 10 6 ∘ F /40 to 41. 1 ∘ C ), tachyarrhythmias (atrial fibrillation with rapid ventricular response in 10–35% of cases), high-output acute decompensated heart failure, extreme agitation, psychosis, delirium, diarrhea, and jaundice from hepatic centrilobular congestion.

Burch-Wartofsky Point Scale (BWPS)

Because serum free T 4 T_4 T 4 ​ and T 3 T_3 T 3 ​ levels do not correlate with clinical severity, thyroid storm is diagnosed clinically using the Burch-Wartofsky Point Scale (BWPS) : BURCH-WARTOFSKY POINT SCALE (BWPS) SCORING

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. Thermoregulatory Dysfunction: 99.0–99.9°F (5 pts) ... >=104.0°F (30 pts)│
  • │ 2. Central Nervous System Effects: Mild agitation (10 pts), Delirium / │
  • │ Psychosis (20 pts), Seizures / Coma (30 pts) │
  • │ 3. Gastrointestinal-Hepatic: Diarrhea / Nausea / Vomiting / Pain (10 pts), │
  • │ Unexplained Jaundice (20 pts) │
  • │ 4. Cardiovascular Dysfunction: │
  • │ • Tachycardia: 99–109 bpm (5 pts) ... >=140 bpm (25 pts) │
  • │ • Congestive Heart Failure: Mild (5 pts), Moderate (10 pts), Severe (15) │
  • │ • Atrial Fibrillation: Present (10 pts) │
  • │ 5. Precipitating Event History: Absent (0 pts), Present (10 pts) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ TOTAL SCORE INTERPRETATION: │
  • │ • < 25 Points: Thyroid Storm Unlikely │
  • │ • 25–44 Points: Impending Thyroid Storm │
  • │ • >= 45 Points: Highly Suggestive of Overt Thyroid Storm (TREAT STAT!) │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Quadruple Drug Sequence for Thyroid Storm

Therapy for thyroid storm must be initiated immediately upon clinical recognition. The pharmacotherapy regimen targets four distinct biochemical checkpoints in a strict sequential order. QUADRUPLE DRUG SEQUENCE IN THYROID STORM

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ STEP 1: BLOCK NEW HORMONE SYNTHESIS (THIONAMIDE) │
  • │ • Propylthiouracil (PTU) 500-1,000 mg load, then 250 mg PO/NG q4h │
  • │ --> Blocks thyroid peroxidase AND peripheral 5'-deiodinase (T4 to T3) │
  • │ • OR Methimazole 20 mg PO/NG q4–6h │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ STEP 2: BLOCK HORMONE RELEASE (INORGANIC IODINE) │
  • │ • SSKI 5 drops PO q6h OR Lugol's Solution 8 drops PO q6h │
  • │ • CRITICAL RULE: MUST WAIT AT LEAST 1 HOUR AFTER STEP 1! │
  • │ --> Prevents Jod-Basedow phenomenon; induces Wolff-Chaikoff effect │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ STEP 3: CONTROL ADRENERGIC HYPERACTIVITY (BETA-BLOCKER) │
  • │ • Propranolol 60–80 mg PO q4h or 1–2 mg IV q10–15m (blocks peripheral T4->T3)│
  • │ • Esmolol IV infusion (load 500 mcg/kg, titrate 50–300 mcg/kg/min) │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ STEP 4: GLUCOCORTICOID SUPPORT & PERIPHERAL CONVERSION BLOCK │
  • │ • Hydrocortisone 100 mg IV q8h OR Dexamethasone 2 mg IV q6h │
  • │ --> Treats relative adrenal exhaustion + blunts peripheral T4 to T3 │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Step 1: Block Synthesis (Thionamides)

Propylthiouracil (PTU) : 500 to 1,000 mg loading dose, then 250 mg PO or NG every 4 hours (2016 American Thyroid Association guideline). PTU is historically preferred over methimazole in acute thyroid storm because it uniquely exerts a dual mechanism: it inhibits thyroid peroxidase (blocking organification and iodotyrosine coupling in the thyroid gland) AND directly inhibits peripheral 5'-monodeiodinase , reducing peripheral conversion of T 4 T_4 T 4 ​ to the active T 3 T_3 T 3 ​ by 20% to 30%.

Methimazole (MMI) : 20 mg PO or NG every 4 to 6 hours . Highly effective organification blocker with a longer half-life, but does not block peripheral T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ conversion. Methimazole is preferred in uncomplicated thyrotoxicosis and for long-term maintenance because PTU carries an FDA boxed warning for fulminant hepatic necrosis.

Step 2: Block Release (Inorganic Iodine) & The 1-Hour Timing Rule

Pharmacology : Administer Saturated Solution of Potassium Iodide (SSKI) (5 drops PO/NG every 6 hours) or Lugol's Solution (8 drops PO/NG every 6 hours). Supraphysiologic concentrations of inorganic iodide transiently block the proteolytic cleavage and release of pre-formed T 4 T_4 T 4 ​ and T 3 T_3 T 3 ​ from thyroglobulin and temporarily suppress organification ( Wolff-Chaikoff effect ).

The Critical 1-Hour Rule : Inorganic iodine must be administered AT LEAST 1 HOUR AFTER the initial dose of thionamide (PTU or methimazole).

The Jod-Basedow Hazard : If inorganic iodine is administered prior to thionamide blockade, the massive influx of exogenous iodine substrate provides fuel for unchecked thyroid peroxidase, stimulating explosive de novo synthesis and release of new thyroid hormones ( Jod-Basedow phenomenon ), which catastrophically worsens thyroid storm.

Step 3: Beta-Adrenergic Receptor Blockade

Propranolol : 60 to 80 mg PO every 4 to 6 hours , or 1 to 2 mg slow IV push every 10 to 15 minutes (maximum 10 mg). Non-selective beta-blocker that counteracts tachycardia, tremor, and agitation. At high doses ( > 160 mg/day >160\text{ mg/day} > 160 mg/day ), propranolol also inhibits peripheral 5'-deiodinase conversion of T 4 T_4 T 4 ​ to T 3 T_3 T 3 ​ .

Esmolol : Continuous IV infusion (loading dose 500 mcg/kg over 1 minute, followed by maintenance titration at 50 to 300 mcg/kg/min ). Ultra-short acting (half-life ~9 minutes); ideal in critically ill patients with borderline hemodynamics, acute decompensated heart failure, or underlying reactive airway disease where rapid titration is critical.

Step 4: Systemic Glucocorticoids

Hydrocortisone 100 mg IV every 8 hours (or 300 mg initial load, then 100 mg q8h), or Dexamethasone 2 mg IV every 6 hours .

Glucocorticoids treat relative adrenal exhaustion driven by the hypermetabolic turnover of endogenous cortisol, provide hemodynamic stability, and synergistically inhibit peripheral T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ monodeiodination.

Antipyresis & Enterohepatic Elimination

Acetaminophen : Primary antipyretic of choice for hyperpyrexia.

Aspirin Contraindication : Aspirin and NSAIDs are strictly contraindicated! Salicylates compete with T 4 T_4 T 4 ​ and T 3 T_3 T 3 ​ for binding sites on thyroid-binding globulin (TBG) and transthyretin, displacing bound thyroid hormones and sharply increasing circulating free, active T 4 T_4 T 4 ​ and T 3 T_3 T 3 ​ concentrations.

Bile Acid Sequestrants : Cholestyramine 4 g orally four times daily binds thyroid hormones undergoing enterohepatic circulation in the gastrointestinal tract, accelerating fecal excretion and lowering free T 4 T_4 T 4 ​ levels.

Myxedema Coma: Pathophysiology & Emergent Pharmacotherapy

Myxedema coma is the extreme fatal culmination of untreated, severe hypothyroidism. It carries a mortality rate of 25% to 50%. The cardinal clinical hallmarks are:

Severe Hypothermia : Core body temperature frequently < 95 ∘ F ( 35 ∘ C ) <95^\circ\text{F} (35^\circ\text{C}) < 9 5 ∘ F ( 3 5 ∘ C ) , and often < 90 ∘ F ( 32.2 ∘ C ) <90^\circ\text{F} (32.2^\circ\text{C}) < 9 0 ∘ F ( 32. 2 ∘ C ) .

Profound Bradycardia & Hypotension : Decreased cardiac inotropy and chronotropy, pericardial effusions, and decreased systemic vascular resistance.

Hypoventilation & Hypercapnia : Blunted ventilatory responses to hypoxia and hypercapnia, macroglossia, and respiratory muscle weakness requiring mechanical ventilation.

Neuropsychiatric Deterioration : Stupor, lethargy, delusions ("myxedema madness"), seizures, and coma.

The Mandatory Glucocorticoid Pre-Treatment Rule

Before administering thyroid hormone, clinicians must address the adrenal axis:

Stress-Dose Hydrocortisone (100 mg IV every 8 hours) must be administered PRIOR TO or SIMULTANEOUSLY WITH intravenous thyroid hormone.

Pathophysiological Hazard : Administering thyroid hormone increases cellular metabolic rate and accelerates the hepatic clearance of endogenous cortisol. If co-existing primary adrenal insufficiency (autoimmune polyglandular syndrome) or secondary hypopituitarism is present, administering thyroid hormone alone will precipitate acute, fatal circulatory collapse ( adrenal crisis ). MYXEDEMA COMA PHARMACOTHERAPY SEQUENCE

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. GLUCOCORTICOID SUPPORT (MANDATORY BEFORE OR WITH THYROID HORMONE) │
  • │ • Hydrocortisone 100 mg IV q8h to prevent precipitating adrenal crisis │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. INTRAVENOUS THYROID HORMONE REPLACEMENT │
  • │ • Levothyroxine (IV T4): 200–400 mcg IV load, then 50–100 mcg daily │
  • │ • +/- Liothyronine (IV T3): 5–20 mcg IV load, then 2.5–10 mcg q8h │
  • │ --> T3 provides immediate active hormone (5'-deiodinase is impaired) │
  • │ --> Use caution with T3 in elderly or severe coronary artery disease │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. SUPPORTIVE CRITICAL CARE │
  • │ • Passive external rewarming only (active rewarming causes vasodilation) │
  • │ • Mechanical ventilation for hypercapnia; D5NS for hypoglycemia/hyponatremia│
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Thyroid Hormone Replacement Strategies

Intravenous Levothyroxine (T4) : Loading dose of 200 to 400 mcg IV , followed by 50 to 100 mcg IV daily until conversion to oral therapy. The large IV loading dose rapidly saturates empty binding sites on thyroid-binding globulin.

Intravenous Liothyronine (T3) : Loading dose of 5 to 20 mcg IV , followed by 2.5 to 10 mcg IV every 8 hours . In severe myxedema coma, the peripheral 5'-deiodinase enzyme that converts T 4 T_4 T 4 ​ to T 3 T_3 T 3 ​ is profoundly downregulated by hypothermia and critical illness. Co-administering T 3 T_3 T 3 ​ provides immediate biologically active hormone. However, in elderly patients or those with coronary artery disease, high doses of T 3 T_3 T 3 ​ can trigger fatal myocardial ischemia or ventricular arrhythmias; doses should be reduced or withheld.

Rewarming Rule : Use passive rewarming blankets only. Active external rewarming produces peripheral vasodilation, precipitating profound distributive shock.

Acute Adrenal Crisis: Emergency Resuscitation

Acute adrenal crisis is a life-threatening state of severe relative or absolute glucocorticoid and mineralocorticoid deficiency. Triggers include septic shock, trauma, surgery, acute myocardial infarction, bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome), or abrupt cessation of chronic exogenous corticosteroid therapy.

Clinical Presentation & Characteristic Electrolyte Pattern

Refractory Hypotensive Shock : Severe distributive shock unresponsive to aggressive crystalloid volume administration and high-dose vasopressor infusions.

Gastrointestinal Symptoms : Severe abdominal pain, rigidity, nausea, and vomiting, frequently mimicking an acute surgical abdomen.

Metabolic Hallmarks : Hyponatremia, Hyperkalemia, Hypoglycemia , and mild non-anion gap metabolic acidosis (due to mineralocorticoid deficiency impairing renal tubular H + H^+ H + and K + K^+ K + excretion and causing renal sodium wasting). ACUTE ADRENAL CRISIS RESUSCITATION

  • ┌─────────────────────────────────────────────────────────────────────────────┐
  • │ 1. VOLUME EXPANSION & GLUCOSE CORRECTION │
  • │ • 1,000–2,000 mL 5% Dextrose in 0.9% Normal Saline (D5NS) in Hour 1 │
  • │ • Corrects intravascular collapse, hyponatremia, and severe hypoglycemia │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 2. DEFINITIVE GLUCOCORTICOID REPLACEMENT │
  • │ • Hydrocortisone 100 mg IV bolus, then 200 mg/24h continuous infusion │
  • │ (or 50 mg IV push q6h) │
  • │ • NOTE: >100 mg/day hydrocortisone saturates mineralocorticoid receptors;│
  • │ fludrocortisone is NOT required in the acute emergency phase │
  • ├─────────────────────────────────────────────────────────────────────────────┤
  • │ 3. DO NOT DELAY STEROIDS FOR TESTING │
  • │ • Draw a random cortisol and ACTH if possible, then treat at once │
  • │ • Dexamethasone 4 mg IV only if hydrocortisone is unavailable, or when │
  • │ an undiagnosed patient must have a cosyntropin test first │
  • └─────────────────────────────────────────────────────────────────────────────┘
  • Glucocorticoid Selection & Dosing

Hydrocortisone (First-Line) : Administer 100 mg IV bolus , followed by 200 mg per 24 hours as a continuous infusion (or 50 mg IV push every 6 hours). At doses ≥ 100 mg/day \ge 100\text{ mg/day} ≥ 100 mg/day , hydrocortisone provides maximal glucocorticoid coverage and exerts cross-over mineralocorticoid receptor saturation equivalent to 0.1 mg of fludrocortisone. Oral fludrocortisone is unnecessary until hydrocortisone is tapered below 50 mg/day.

Never Delay Treatment for Testing : The 2016 Endocrine Society guideline on primary adrenal insufficiency says to give hydrocortisone immediately in suspected adrenal crisis. Draw a random cortisol and ACTH first if this can be done without delay. In a patient with known Addison disease or long-term steroid use, no diagnostic test is needed.

Dexamethasone (Limited Role) : Dexamethasone 4 mg IV does not cross-react with cortisol immunoassays, so it is sometimes chosen when an undiagnosed patient must have a cosyntropin stimulation test before treatment, or when hydrocortisone is unavailable. It has essentially no mineralocorticoid activity , which matters in primary adrenal insufficiency with hyponatremia and hyperkalemia. Switch to hydrocortisone as soon as testing is done.